We use essential cookies and third-party cookies for content.

The National Times - Disney earnings boosted by theme parks, as CEO handover nears

Disney earnings boosted by theme parks, as CEO handover nears

ECONOMY 02.02.2026
Disney earnings boosted by theme parks, as CEO handover nears
Disney earnings boosted by theme parks, as CEO handover nears / Photo: © AFP/File

The Walt Disney Company on Monday reported quarterly earnings showing that streaming services gained momentum and theme-park revenue hit record levels, but the company warned of a possible slowdown in the United States.

Change text size:

Net profit reached $2.48 billion, down 6 percent year-over-year, according to a statement, with the Experiences division -- Disney's theme parks and resorts -- delivering record quarterly revenue of $10.0 billion.

US parks, including Disney World, showed 8 percent operating income growth for the quarter that ended December 31, with attendance up 1 percent and per capita spending up 4 percent.

Cruises performed strongly, thanks to an increase in passenger numbers and the addition of a new ship, the Disney Destiny, the seventh in the group's fleet.

Disney nevertheless warned that operating income for the parks and cruises division could see "modest" growth during the current quarter, due in particular to unfavorable factors, including headwinds in demand from foreign tourists at US parks.

The number of foreign visitors to the United States fell by 2.5 percent in 2025 compared to the previous year, according to the US Department of Commerce. The country has seen eight consecutive months of decline.

After an initial surge, the stock plunged and was down about 5 percent on Wall Street.

Operating income for the entertainment giant's Disney+ and Hulu streaming services grew 72 percent from the same quarter a year ago to $450 million, well above expectations.

Like Netflix, Disney no longer gives subscriber numbers for its streaming platforms, but the boost in revenue is largely attributed to a hike in prices.

The Entertainment segment overall saw operating income plunge 35 percent to $1.1 billion, as higher programming and marketing costs offset the gains from blockbuster theatrical releases including "Zootopia 2" and "Avatar: Fire and Ash."

"Zootopia 2" notably became the highest-grossing foreign film of all time in China, where the franchise is an important driver of attendance at Shanghai Disneyland, the company said.

"We are pleased with the start to our fiscal year, and our achievements reflect the tremendous progress we've made," CEO Bob Iger said in the statement.

Iger said the company had high hopes for its slate of upcoming movies, including a sequel to "The Devil Wears Prada," "The Mandalorian and Grogu," "Toy Story 5," and a live-action "Moana."

Iger is expected to announce his plans to step aside as CEO by the end of the year as early as this week, according to reports.

He previously resigned as Disney CEO in February 2020 after 15 years, handing control to Bob Chapek.

But their clashes during the Covid-19 pandemic led to Chapek's ouster in November 2022 and Iger's return as CEO.

In a recent public filing, Disney said internal candidates are currently being mentored by Iger and receiving guidance from external coaches.

The head of the highly profitable parks and cruises unit, Josh D'Amaro, is a leading candidate to replace Iger.

M.Davis--TNT

Featured

Carney touts Canada 'pivot' away from US as Trump levels new threat

Canadian Prime Minister Mark Carney said Tuesday that reducing economic ties with the United States would come at a cost but the benefits were clear, as President Donald Trump threatened new penalties targeting Canada.

Nearly 1,100 flights cancelled after UK air traffic control glitch

Almost 1,100 flights to and from UK airports were cancelled Tuesday due to what the country's air traffic control service called a technical issue, in the latest glitch to spark travel chaos.

Carney touts Canada 'pivot' away from US as tariffs rise

Canadian Prime Minister Mark Carney on Tuesday said reducing economic ties with the United States would come at a cost but the long-term benefits were clear, as retaliatory tariffs on US products took effect.

The "Everlasting Battery" Inside Your Joints:UConn Professor's Self-Powered Healing Material just Got Acquired

A material that turns your own movement into medicine has just landed a corporate home. PetVivo Holdings (OTCQX: PETV), a veterinary biotech and biomedical device company focused on treating osteoarthritis in dogs and horses, has acquired PiezoBioMembrane (PBM) — a startup built around a biodegradable implant that generates electricity from the everyday force of a joint in motion, and uses that charge to help regrow cartilage from the inside out. The material is the invention of Thanh Nguyen, a professor of mechanical engineering in UConn's College of Engineering, who founded PBM in 2021 to advance new implementation methods for his work with piezoelectric materials — substances that convert mechanical force into electrical energy. These materials are typically ceramics: hard, brittle, and poorly suited for medical use. But Nguyen's lab developed new forms that are so , flexible, and biodegradable, breaking down naturally within the body over time. wound healing, The materials have already shown strong potential across a range of medical applications, including tissue regeneration, implanted force sensors, and targeted drug delivery in tumor treatment. How It Works biodegradable ultrasound for In the case of arthritis, Nguyen explains, the piezoelectric materials function as an off-the-shelf product that can be implanted or injected directly into the ailing joint — with no drugs, chemicals, or cells required. The everyday force exerted on the joint generates a small electrical charge, which helps regrow healthy cartilage, mimicking the body's natural use of electricity to regenerate tissue. "The body can be electrically stimulated to regrow," Nguyen says. PBM's materials "act like a battery — an everlasting battery that works whenever there is a force applied, and vanishes safely inside the body over time." PetVivo's Vision for the Acquisition PetVivo Holdings CEO John Lai expressed enthusiasm for the merger's potential to improve the lives of companion animals globally. "PBM has developed a compelling functional biomaterials platform with the potential to support the development of multiple medical device and therapeutic product lines across both human and animal health markets," Lai said in a press release. "By combining PBM's scientific innovation with PetVivo's product development capabilities, commercialization experience, regulatory expertise, and public company infrastructure, we believe we can accelerate theadvancement of technologies that may serve as the foundation for numerous future products and strategic opportunities." For Nguyen, the deal is a chance to scale technology that could eventually benefit both animals and people. "PetVivo is an animal health company, but they do have a big passion: pushing the technology towards clinical trials for human use," Nguyen says. "That aligned perfectly with my passion for developing technology that has an impact on human life. That is why I am excited about this merger, which facilitates my passion." A Track Record of Innovation Nguyen's research sits at the intersection of medicine, micro/nanotechnology, and biomaterials. His inventions have earned him publications in prominent scientific journals and media coverage from outlets including NPR. Nguyen founded PBM during the COVID-19 pandemic, a er realizing the material he had developed could be used to create an especially effective, biodegradable face mask — one where the mechanical force of breathing generated an electrical charge that provided an extra layer of protection against viruses. PBM is not Nguyen's only venture in the acquisition pipeline. His other startup, Single-Time Microneedles (STM), is also currently undergoing an acquisition process. STM has pioneered stable, efficient vaccine delivery technology in the form of an adhesive patch. shelfNguyen's focus on biodegradable materials has translated into a remarkably diverse range of medical applications. He has received five R01 grants from the National Institutes of Health (NIH) supporting research in cartilage regeneration, bone regeneration, HIV antibody delivery systems, and biodegradable ultrasound technology to boost the effectiveness of chemotherapy for brain cancer. "Whatever we are working on, we want to show that it works very well in vitro and in vivo," Nguyen says. "Then, when we are at the point of commercialization, we set up a startup or license the technology — or maybe team up with an industry partner." Thanh Nguyen is a professor of mechanical engineering in UConn's College of Engineering. (Courtesy of Thanh Nguyen

Change text size: